The CSL Behring Commitment

CSL Behring is committed to furthering its role as a scientific leader in the area of von Willebrand disease (VWD). Click on the links below to find out more about CSL Behring’s ongoing commitment to the scientific community and to patient health.

VWD Physician Advisory Board
Our expert panel is made up of 10 to 12 hematologists and ob/gyns—key opinion leaders in VWD. They are dedicated to a single, overall goal: improving treatment therapies for VWD.

VWD Consumer Advisory Committee
This consumer panel is composed of VWD patients and parents from across the country, who meet regularly to share VWD-related interests and needs.

CSL Behring Foundation for Research and Advancement of Patient Health
This is the only nonprofit foundation dedicated exclusively to charitable, scientific, and educational endeavors that benefit the bleeding disorders community. The Foundation provides grants for research projects and community initiatives that advance the standard of care for people with bleeding disorders.

Grants
The CSL Behring Foundation provides grants to fund further research on VWD for the advancement of patient health.

CSL Assurance Program
This program is designed to ensure that people who rely on Humate-P^® can continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Project Red Flag
CSL Behring is the founding sponsor for Project Red Flag, the National Hemophilia Foundation's (NHF) public awareness campaign to educate women and health care providers about bleeding disorders in women. The program partner for Project Red Flag is the Centers for Disease Control and Prevention (CDC).

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also in indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.